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EDITORIAL
Tuberculosis: A Global Health Problem
Tuberculosis (TB) is an ancient disease that has af-
fected mankind for more than 4,000 years (1). It 
is a chronic disease caused by the bacillus Myco-
bacterium tuberculosis and spreads from person to 
person through air. TB usually affects the lungs but 
it can also affect other parts of the body, such as 
brain, intestines, kidneys, or the spine. Symptoms 
of TB depend on where in the body the TB bacteria 
are growing. In the cases of pulmonary TB, it may 
cause symptoms, such as chronic cough, pain in 
the chest, haemoptysis, weakness or fatigue, weight 
loss, fever, and night-sweats.  
TB remains a leading cause of morbidity and 
mortality in developing countries, including Ban-
gladesh. With the discovery of chemotherapy in 
the 1940s and adoption of the standardized short 
course in the 1980s, it was believed that TB would 
decline globally. Although a declining trend was 
observed in most developed countries, this was not 
evident in many developing countries (2). In devel-
oping countries, about 7% of all deaths are attrib-
uted to TB which is the most common cause of 
death from a single source of infection among 
adults (3). It is the first infectious disease declared 
by the World Health Organization (WHO) as a 
global health emergency (4). In 2007, it was es-
timated globally that there were 9.27 million in-
cident cases of TB, 13.7 million prevalent cases, 
1.32 million deaths from TB in HIV-negative and 
0.45 million deaths in HIV-positive persons (5). 
Asia and Africa alone constitute 86% of all cases 
(5). Bangladesh ranked the 6th highest for the 
burden of TB among 22 high-burden countries in 
2007, with 353,000 new cases, 70,000 deaths, and 
an incidence of 223/100,000 people per year (5).   
Implementation of directly-observed therapy short 
course (DOTS) has been a ‘breakthrough’ in the 
control of tuberculosis. In many countries, it 
has become the cornerstone in the treatment 
of tuberculosis. The number of countries and the 
coverage of DOTS within the countries have in-
creased over the years (5). Over the last 15 years, 
about 35 million people have been cured, and 
eight million deaths have been averted with the 
adoption of DOTS (6). Implementation of DOTS 
was started in 1993 in Bangladesh, and it gradually 
covered the whole country (7).  
Men are more commonly affected than women. 
The case notifications in most countries are higher 
in males than in females. There were 1.4 million 
smear-positive TB cases in men and 775,000 in 
women in 2004 (8). The ratio of female to male TB 
cases notified globally is 0.47:0.67 (9). The reasons 
for these gender differences are not clear. These may 
be due to differences in the prevalence of infection, 
rate of progression from infection to disease, un-
der-reporting of female cases, or the differences in 
access to services. 
The association between poverty and TB is well-
recognized, and the highest rates of TB were found 
in the poorest section of the community (10). TB 
occurs more frequently among low-income people 
living in overcrowded areas and persons with little 
schooling (11). Poverty may result in poor nutri-
tion which may be associated with alterations in 
immune function. On the other hand, poverty 
resulting in overcrowded living conditions, poor 
ventilation, and poor hygiene-habits is likely to in-
crease the risk of transmission of TB (12). 
Various surveys have been conducted to under-
stand the knowledge, attitudes, and practices re-
garding tuberculosis (13-14). One survey in India 
reported that most (93%) people had heard of TB 
but only 20.5% of the people demonstrated suffi-
cient knowledge of TB (13). This issue of the Journal 
includes an article by Rundi who explored health-
care-seeking behaviour with regard to TB among the 
people of Sabah in East Malaysia and the impact of 
TB on patients and their families (15). The author 
used qualitative methods and interviewed patients 
with TB and their relatives. It was found that most 
(96%) respondents did not know the cause of TB. 
TB also affected life-styles of the people. The author 
emphasized the need to understand the reasons for 
misconceptions about TB and to address it through 
health education.       Zaman K Tuberculosis
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Better understanding of the prevalence of drug 
resistance against tuberculosis is one of the key 
elements in the control of TB. Drug resistance, in 
combination with other factors, results in increased 
morbidity and mortality due to tuberculosis. Drug-
resistant strains of TB is rapidly emerging world-
wide (16). The WHO reported alarming rise of not 
only multidrug-resistant (MDR) TB but also of XDR 
TB (extreme drug-resistant TB) globally. Both treat-
ment and management of such cases are well be-
yond the capacity of any developing country. Glob-
ally, there were about 0.5 million cases of MDR TB. 
In Bangladesh, the MDR rate is 3.5% among new 
cases and 20% among previously-treated cases (5). 
The death rate in MDR cases is high (50-60%) and 
is often associated with a short span of disease (4-16 
weeks) (17). Several factors have been identified for 
the development of MDR cases. These include non-
adherence to therapy, lack of direct observed treat-
ment, limited or interrupted drug supplies, poor 
quality of drugs, widespread availability of anti-TB 
drugs without prescription, poor medical manage-
ment, and poorly-managed national control pro-
grammes (18-20). Continuation of the existing 
MDR surveillance is important to effectively plan 
for the treatment of MDR cases and implementa-
tion of the DOTS-Plus strategy. It requires rapid, 
concerted action and close collaboration among 
government, non-government and private organi-
zations to control MDR tuberculosis (21). 
The diagnosis of TB among children is difficult. 
Moreover, young children cannot produce sputum. 
Estimates indicate that children constitute about 
10% of all new cases in high-burden areas (8). Clini-
cal signs and symptoms and scoring system have 
been used for the diagnosis of TB among children 
(22). Various diagnostic techniques have been used 
for improving the diagnosis among children. These 
include culture, serodiagnosis, and nucleic acid am-
plification (23).
Many countries use BCG vaccine as part of their 
TB-control programme. The protective efficacy of 
BCG viccine against all forms of TB is about 50% 
but it was more in serious forms of infection (64% 
in cases of tuberculosis meningitis and 78% in dis-
seminated infection) (24). Several new vaccines 
against TB are being developed. These vaccines 
are now being field-tested in different countries 
in different phases (25). 
There are several challenges which need to be ad-
dressed for effective control of TB, particularly in 
developing countries. These include the devel-
opment of an effective surveillance system, acceler-
ated identification of cases, expansion of DOTS 
to hard-to-reach areas, strengthening of DOTS in 
urban settings, ensuring adequate staff and labo-
ratory facilities, involvement of private practitio-
ners, treatment facilities for MDR cases, identifica-
tion of TB among children and extra-pulmonary 
cases,  and  effective  coordination  among  health-
care providers (5,26-27). Moreover, the prevalence 
of TB is influenced by HIV, and effective control 
measures are needed for both the diseases.  
Further research is warranted to improve diagnos-
tics, develop new drugs and vaccines, simple and 
effective regimen for simultaneous treatment 
of TB and HIV, ways to improve programme ef-
fectiveness, and better understanding of the re-
lationship between TB and chronic diseases, e.g. 
diabetes and smoking, and identify social and 
behavioural factors which limit the detection of 
cases (8,28). 
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